Treatment of osteoporosis with denosumab in patients with decreased kidney function
ConclusionTreatment with denosumab of osteoporosis in patients with decreased kidney function (eGFR 9 –50 mL/min), with normal/high PTH, seems in general to be well tolerated, with improvement of bone and decreased risk of new fractures.
Source: Archives of Orthopaedic and Trauma Surgery - Category: Orthopaedics Source Type: research
More News: Denmark Health | Endocrinology | Hormones | Orthopaedics | Osteoporosis | Study | Urology & Nephrology | Xgeva